Pernicious Anemia Diagnosis and Treatment Market Report 2026

The pernicious anemia diagnosis and treatment market size has grown strongly in recent years. It will grow from $1.51 billion in 2025 to $1.62 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to high incidence of hospital-acquired infections, reliance on conventional iv catheters, growing patient population requiring iv therapy, limited availability of advanced safety catheters, fragmented healthcare infrastructure.

The pernicious anemia diagnosis and treatment market size is expected to see strong growth in the next few years. It will grow to $2.09 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in safety iv catheter technologies, increasing adoption of smart and antimicrobial catheters, expansion of home healthcare services, rising preference for integrated/closed iv systems, growing demand for minimally invasive therapy administration. Major trends in the forecast period include increasing adoption of ai-based catheter insertion guidance systems, rising use of cloud-based patient monitoring for iv therapy, growing development of antimicrobial and smart catheters, increasing integration of iot-enabled devices for iv monitoring, rising implementation of smart manufacturing for peripheral iv catheters.

The increasing prevalence of vitamin B12 deficiency is expected to support the growth of the pernicious anemia diagnosis and treatment market in the coming years. Vitamin B12 deficiency occurs when the body does not have sufficient levels of the vitamin required to produce healthy red blood cells, resulting in symptoms such as fatigue, weakness, and neurological complications. The incidence of vitamin B12 deficiency is rising due to the growing adoption of plant-based diets, which often lack adequate natural sources of vitamin B12 and may lead to insufficient intake without proper supplementation. Vitamin B12 deficiency directly influences pernicious anemia diagnosis and treatment, as reduced B12 levels impair red blood cell production and prompt clinicians to prescribe vitamin B12 supplementation as a primary and effective therapeutic approach. For instance, in February 2023, according to a report published by the National Health Service (NHS), a UK-based government health organization, vitamin B12 and folate deficiencies are more common among older adults, affecting approximately 1 in 10 individuals aged 75 years or older and 1 in 20 people aged 65 to 74 years. Therefore, the rising prevalence of vitamin B12 deficiency is contributing to the growth of the pernicious anemia diagnosis and treatment market.

Major companies operating in the pernicious anemia diagnosis and treatment market are concentrating on the development of advanced solutions, such as vitamin B12 maintenance therapy options, to enhance patient adherence and support long-term disease management. Vitamin B12 maintenance therapy involves continuous supplementation through oral tablets, injections, or nasal sprays to maintain adequate B12 levels and prevent the recurrence of deficiency-related symptoms. For example, in February 2024, Lupin Pharmaceuticals Inc., an India-based pharmaceutical company, introduced cyanocobalamin nasal spray at a dosage of 500 mcg per spray, offering a non-invasive alternative for vitamin B12 supplementation. This nasal spray provides a convenient and effective option for patients with pernicious anemia who have difficulty with oral vitamin B12 formulations, improves vitamin B12 absorption, and supports better management of vitamin B12 deficiency, thereby improving patient compliance and treatment outcomes.

In February 2025, Lightstone Group, a US-based investment firm, acquired Pfizer’s Durham facility for $41.1 million. This acquisition enabled the addition of a move-in-ready, state-of-the-art clinical supply cGMP facility designed to meet high-quality manufacturing standards to Lightstone Group’s expanding portfolio. Pfizer Inc. is a US-based manufacturer of vitamin B12 capsules used in the treatment of pernicious anemia.

Major companies operating in the pernicious anemia diagnosis and treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Lupin Limited, Eli Lilly and Company, DSM Nutritional Products AG, Bio-Rad Laboratories Inc., CSL Vifor Pharma, Par Pharmaceutical Companies Inc., AdvaCare Pharma, Monobind Inc., Merck KGaA, Abbott Laboratories, Siemens Healthineers AG, Ortho Clinical Diagnostics Inc., Quest Diagnostics Incorporated, Bio-Techne Corporation.

North America was the largest region in the pernicious anemia diagnosis and treatment market in 2025. The regions covered in the pernicious anemia diagnosis and treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pernicious anemia diagnosis and treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the peripheral iv catheters market by increasing costs of imported catheters, smart devices, and antimicrobial components, particularly in North America and Europe. This has temporarily slowed adoption in hospitals and clinics, while also encouraging domestic manufacturing, promoting innovation in cost-effective safety and smart catheter solutions, and strengthening supply chain resilience across healthcare delivery channels.

The pernicious anemia diagnosis and treatment market research report is one of a series of new reports that provides pernicious anemia diagnosis and treatment market statistics, including pernicious anemia diagnosis and treatment industry global market size, regional shares, competitors with a pernicious anemia diagnosis and treatment market share, detailed pernicious anemia diagnosis and treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pernicious anemia diagnosis and treatment industry. This pernicious anemia diagnosis and treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pernicious anemia diagnosis and treatment involves the identification and management of a condition in which the body is unable to produce sufficient healthy red blood cells due to impaired absorption of vitamin B12, commonly associated with a lack of intrinsic factor. Diagnosis includes evaluation of clinical symptoms such as fatigue, weakness, and neurological issues. Treatment is aimed at replenishing vitamin B12 levels to support normal red blood cell formation, alleviate symptoms, and prevent long-term health complications.

The primary types of pernicious anemia diagnosis and treatment include complete blood count tests, vitamin B12 deficiency tests, and intrinsic factor deficiency tests. A complete blood count (CBC) test is a routinely used blood test that measures different components of the blood and helps detect abnormal red blood cell and hemoglobin levels, which are typical indicators of anemia and aid in diagnosis. Treatment options include vitamin B12 injections, vitamin B12 tablets, and nasal sprays, which are administered through various routes such as injectable, oral, and intranasal. These diagnostic and treatment approaches are used by end users including hospitals, clinics, diagnostic centers, and others.

The pernicious anemia diagnosis and treatment market consists of revenues earned by entities by providing services such as antibody testing, neurological evaluation services, nutritional counseling, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The pernicious anemia diagnosis and treatment market also includes sales of methylcobalamin supplements, combination supplements, and anemia management trackers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.